suramin has been researched along with Malignant Melanoma in 7 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The results of the current study suggest that combining suramin with receptor-directed therapies offers a more effective regimen for the treatment of malignant melanoma." | 7.70 | Combining suramin and a chimeric toxin directed to basic fibroblast growth factor receptors increases therapeutic efficacy against human melanoma in an animal model. ( Davol, PA; Frackelton, AR; Garza, S, 1999) |
| "Our previous work showed that sphingosine 1-phosphate (Sph-1-P) inhibits the cell motility of mouse melanoma B16/F10, and other types of cells at 10-100 nM concentrations." | 7.69 | Sphingosine 1-phosphate regulates melanoma cell motility through a receptor-coupled extracellular action and in a pertussis toxin-insensitive manner. ( Hakomori, S; Igarashi, Y; Ruan, F; Sweeney, EA; Yamamura, S; Yatomi, Y, 1997) |
| "Suramin is a polysulfonated drug with several biological activities including inhibition of binding of some growth factors to cells, inhibition of tumor cell growth, and of glycosaminoglycan metabolism." | 5.28 | Suramin inhibits laminin- and thrombospondin-mediated melanoma cell adhesion and migration and binding of these adhesive proteins to sulfatide. ( Kohn, EC; Roberts, DD; Zabrenetzky, VS, 1990) |
| "The results of the current study suggest that combining suramin with receptor-directed therapies offers a more effective regimen for the treatment of malignant melanoma." | 3.70 | Combining suramin and a chimeric toxin directed to basic fibroblast growth factor receptors increases therapeutic efficacy against human melanoma in an animal model. ( Davol, PA; Frackelton, AR; Garza, S, 1999) |
| "Our previous work showed that sphingosine 1-phosphate (Sph-1-P) inhibits the cell motility of mouse melanoma B16/F10, and other types of cells at 10-100 nM concentrations." | 3.69 | Sphingosine 1-phosphate regulates melanoma cell motility through a receptor-coupled extracellular action and in a pertussis toxin-insensitive manner. ( Hakomori, S; Igarashi, Y; Ruan, F; Sweeney, EA; Yamamura, S; Yatomi, Y, 1997) |
| "Significant neurologic toxicity can result from therapy with suramin, even when dosing is designed to avoid exposure to plasma concentrations greater than 350 micrograms/mL." | 2.68 | Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin. ( Bitton, RJ; Bowden, C; Cooper, MR; Dalakas, MC; Figg, WD; Headlee, D; Myers, CE; Reed, E; Venzon, DJ, 1995) |
| "Suramin is a polysulfonated drug with several biological activities including inhibition of binding of some growth factors to cells, inhibition of tumor cell growth, and of glycosaminoglycan metabolism." | 1.28 | Suramin inhibits laminin- and thrombospondin-mediated melanoma cell adhesion and migration and binding of these adhesive proteins to sulfatide. ( Kohn, EC; Roberts, DD; Zabrenetzky, VS, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bitton, RJ | 1 |
| Figg, WD | 1 |
| Venzon, DJ | 1 |
| Dalakas, MC | 1 |
| Bowden, C | 1 |
| Headlee, D | 1 |
| Reed, E | 1 |
| Myers, CE | 1 |
| Cooper, MR | 1 |
| Davol, P | 1 |
| Beitz, JG | 1 |
| Frackelton, AR | 2 |
| Wong, P | 1 |
| Bangert, JL | 1 |
| Levine, N | 1 |
| Yamamura, S | 1 |
| Yatomi, Y | 1 |
| Ruan, F | 1 |
| Sweeney, EA | 1 |
| Hakomori, S | 1 |
| Igarashi, Y | 1 |
| Faure, E | 1 |
| Davol, PA | 1 |
| Garza, S | 1 |
| Zabrenetzky, VS | 1 |
| Kohn, EC | 1 |
| Roberts, DD | 1 |
1 trial available for suramin and Malignant Melanoma
| Article | Year |
|---|---|
Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin.
Topics: Adult; Aged; Aged, 80 and over; Humans; Logistic Models; Male; Melanoma; Middle Aged; Motor Neuron D | 1995 |
6 other studies available for suramin and Malignant Melanoma
| Article | Year |
|---|---|
Autocrine down-regulation of basic fibroblast growth factor receptors causes mitotoxin resistance in a human melanoma cell line.
Topics: Down-Regulation; Drug Resistance; Fibroblast Growth Factor 2; Humans; Melanoma; Plant Proteins; Rece | 1995 |
A papulovesicular eruption in a man receiving chemotherapy for metastatic melanoma. Squamous syringometaplasia (squamous metaplasia) of the eccrine glands.
Topics: Aged; Eccrine Glands; Humans; Male; Melanoma; Metaplasia; Skin; Suramin; Urticaria | 1993 |
Sphingosine 1-phosphate regulates melanoma cell motility through a receptor-coupled extracellular action and in a pertussis toxin-insensitive manner.
Topics: Animals; Binding Sites; Carrier Proteins; Cell Movement; Extracellular Space; Lysophospholipids; Mel | 1997 |
X-rays-induced secretion of cellular factor(s) that enhance(s) HIV-1 promoter transcription in various non-irradiated transfected cell lines.
Topics: 3T3 Cells; Animals; Antioxidants; Apoptosis; Cell Line; Chloramphenicol O-Acetyltransferase; Fibrobl | 1998 |
Combining suramin and a chimeric toxin directed to basic fibroblast growth factor receptors increases therapeutic efficacy against human melanoma in an animal model.
Topics: Animals; Antineoplastic Agents; Drug Therapy, Combination; Fibroblast Growth Factor 2; Humans; Male; | 1999 |
Suramin inhibits laminin- and thrombospondin-mediated melanoma cell adhesion and migration and binding of these adhesive proteins to sulfatide.
Topics: Binding Sites; Cell Adhesion; Cell Movement; Heparin; Humans; Laminin; Melanoma; Membrane Glycoprote | 1990 |